Evidence map›Paper›PMID 26032155›Full record

ArticleThe American journal of gastroenterology2015

The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.

I M Modlin, M Kidd, L Bodei, I Drozdov, H Aslanian

Registry-linked trialAbstract readComparative Study
PubMed Publisher
In one paragraph

Article in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03012789 (Diagnosis of Neuroendocrine Neoplasms and Assessment of Response to Surgery by Means of Measurement of Gene Transcripts in Blood), which is not on this map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03012789 nacompletednot on this mapstarted 2017, after this paper: background citation

Diagnosis of Neuroendocrine Neoplasms and Assessment of Response to Surgery by Means of Measurement of Gene Transcripts in Blood

TypeinterventionalSponsorWren Laboratories LLCRan2017 to 2026Enrolled30ConditionsNeuroendocrine Tumor, GastroenteropancreaticArmsSurgery
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. PET/MRI imaging in neuroendocrine neoplasm.Abdominal radiology (New York) · 2023
    Review
  6. Review
  7. PET/CT and PET/MRI in neuroendocrine neoplasms.Abdominal radiology (New York) · 2022
    Review
  8. Article
  9. Observational
  10. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  11. Review
  12. Article
  13. Article
  14. Carcinoid Tumors: Past, Present, and Future.Indian journal of surgical oncology · 2020
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

I M Modlin1] Department of Surgery, Yale University School of Medicine, New Haven, Connecticut, USA [2] Wren Laboratories, Branford, Connecticut, USA.
M KiddWren Laboratories, Branford, Connecticut, USA.
L BodeiDivision of Nuclear Medicine, European Institute of Oncology (IEO), Milan, Italy.
I DrozdovWren Laboratories, Branford, Connecticut, USA.
H AslanianSection of Digestive Diseases, Yale University, New Haven, Connecticut, USA.
Wren Laboratories (United States) · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCurrent monoanalyte blood-based biomarkers for the diagnosis and follow-up of neuroendocrine tumors (NETs) do not achieve satisfactory metrics of sensitivity and specificity. We report the sensitivity and selectivity of the PCR-based test, the NETest, to detect tumors with reference to other benign and malignant gastrointestinal diseases.

methodsA total of 179 cases (gastrointestinal tumors: n=81; pancreatic disease: n=98) were prospectively collected and assessed using the NETest or chromogranin A (CgA) to determine metrics for detecting small intestinal and pancreatic NETs.

resultsFor intestinal carcinoids, the accuracy of the NETest was 93% (all NETs positive and 3 (12%) colorectal tumors were positive). CgA was positive in 80%, but 29% (n=7) of colorectal cancers were CgA positive. For pancreatic disease, the NETest accuracy was 94% (96% NETs positive, 2 (6%) of intraductal papillary mucinous neoplasms (IPMNs) were positive). The accuracy of CgA was 56% (29% of pancreatic NETs were CgA positive). Overall, the NETest was significantly more sensitive than CgA for the detection of small intestinal (area under the curve 0.98 vs. 0.75 P<0.0001) and pancreatic NETs (0.94 vs. 0.52, P<0.0001). NETest scores were elevated (P<0.05) in extensive disease and were more accurate (76-80%) than CgA levels (20-32%). The metrics of the multianalyte NETest met the performance criteria proposed by the National Institutes of Health for biomarkers, whereas CgA measurement did not.

conclusionsThis study demonstrates that a blood-based multianalyte NET gene transcript measurement of well-differentiated small intestinal and pancreatic neuroendocrine tumor disease is sensitive and specific and outperforms the current monoanalyte diagnostic strategy of plasma CgA measurement.

Indexed as

AdenocarcinomaAdultAgedAged, 80 and overArea Under CurveBiomarkers, TumorChromogranin AFemaleGastrointestinal NeoplasmsGene Expression ProfilingHumansMaleMiddle AgedNeuroendocrine TumorsPancreatic CystPancreatic NeoplasmsBiomarkers, TumorChromogranin A

Identifiers

PMID26032155
OpenAlexW1963249638

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.